Related references
Note: Only part of the references are listed.
Article
Multidisciplinary Sciences
Sandile Cele et al.
Summary: The study found that the Omicron variant has reduced neutralizing effectiveness in individuals vaccinated with Pfizer BNT162b2, but those who had previously been infected with SARS-CoV-2 showed better neutralization against Omicron.
Article
Multidisciplinary Sciences
Lihong Liu et al.
Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.
Letter
Medicine, General & Internal
Xin Zhao et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Jingwen Ai et al.
Summary: This study explored the immunogenicity of different vaccination strategies against the Omicron variant of SARS-CoV-2. The results showed that the Omicron variant has a high immune escape ability compared to other variants, but heterologous protein subunit vaccines and homologous inactivated vaccine boosters can improve neutralization against Omicron.
EMERGING MICROBES & INFECTIONS
(2022)
Article
Immunology
Youchun Wang et al.
Summary: The Omicron variant shows greater potential for immune escape compared to other variants, suggesting a significant impact on immunity from previous infections and vaccines.
EMERGING MICROBES & INFECTIONS
(2022)
Article
Cell Biology
Yu Liang et al.
Summary: The emergence of SARS-CoV-2 variants underscores the importance of developing vaccines with broad protection. In this study, a mutation-integrated trimeric form of spike receptor-binding domain (mutI-tri-RBD) was developed as a broadly protective vaccine candidate. The vaccine showed high neutralizing antibody activity against the Delta and Beta variants, as well as the prototype strain, and demonstrated potent protection in hACE2-transgenic mice challenged with live virus.
Article
Immunology
Helen Parry et al.
Summary: Delaying the second dose of the BNT162b2 vaccine can significantly boost antibody response in older people, providing a longer period of protection and delaying the need for booster vaccination. However, in terms of cellular-specific response, the best results were achieved with the standard vaccine interval.
Article
Infectious Diseases
Deborah Cromer et al.
Summary: By analyzing data on in-vitro neutralization and clinical protection, the study found that neutralizing activity against the ancestral SARS-CoV-2 is highly correlated with neutralization of variants of concern, and can still predict the vaccine's protection against these variants. Simulation results suggest that booster vaccination for previously infected individuals can provide higher levels of protection compared to primary vaccination. Although the protection may decrease within the first year after vaccination, the current vaccines can still offer robust protection in the medium term.
Article
Biochemistry & Molecular Biology
Maria Noel Badano et al.
Summary: This study analyzed the humoral response to the BBIBP-CorV vaccine in healthcare workers in Argentina. It found that antibody concentrations significantly increased after both the first and second doses of the vaccine. Individuals with prior SARS-CoV-2 infection had higher antibody titers after a single dose compared to naive subjects after two doses. However, antibody levels declined three months after the second dose.
MOLECULAR IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Xiaoqi Yu et al.
Summary: This study characterizes the neutralizing antibody response to the inactivated SARS-CoV-2 vaccine BBIBP-CorV and assesses its functionality against a range of key SARS-CoV-2 variants. The results show that vaccine-elicited sera have varying degrees of reduction in neutralization against multiple variants, indicating the potential need for additional boost vaccinations.
NATURE COMMUNICATIONS
(2022)
Article
Chemistry, Multidisciplinary
Mehmet Onur Aydogdu et al.
Article
Immunology
Marc Lipsitch et al.
Summary: The study evaluates the impact of breakthrough SARS-CoV-2 infections in vaccinated individuals and discusses the challenges in measuring breakthrough infections and determining the factors affecting vaccine effectiveness. The research also addresses key questions on transitioning to endemicity, tracking viral variants, identifying immune correlates of protection, and dealing with public health challenges in countering breakthrough infections amid global vaccine shortages.
NATURE REVIEWS IMMUNOLOGY
(2022)
Article
Infectious Diseases
Shengli Xia et al.
Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.
LANCET INFECTIOUS DISEASES
(2021)
Editorial Material
Multidisciplinary Sciences
Ravindra K. Gupta et al.
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Medicine, General & Internal
Nawal Al Kaabi et al.
Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Immunology
Kristen A. Earle et al.
Summary: The study found a strong correlation between antibody titers and efficacy when assessing different COVID-19 vaccines, supporting the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.
Article
Multidisciplinary Sciences
Alexander A. Cohen et al.
Summary: The study developed nanoparticles displaying the receptor binding domain (RBD) of SARS-CoV-2 and other animal coronaviruses, which induced cross-reactive antibody responses in mice. Immunization with mosaic RBD nanoparticles resulted in superior neutralization of heterologous viruses, providing a potential strategy for simultaneous protection against multiple coronaviruses.
Article
Biochemistry & Molecular Biology
Hui Wang et al.
Article
Immunology
Masaru Kanekiyo et al.
Article
Biochemistry & Molecular Biology
Dan H. Barouch et al.
